IPSEN (OTCMKTS:IPSEY) Stock Price Crosses Above 200-Day Moving Average - Should You Sell?

Key Points

• IPSEN's share price has crossed above its 200-day moving average of $29.84, trading as high as $34.10 on Monday.
• The stock's current trading volume reached 3,726 shares, with shares last priced at $34.03.
• IPSEN is involved in the development of treatments in areas such as oncology, neuroscience, and rare diseases, with several products in various phases of clinical trials.

IPSEN (OTCMKTS:IPSEY - Get Free Report)'s share price crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $29.84 and traded as high as $34.10. IPSEN shares last traded at $34.03, with a volume of 3,726 shares trading hands.

IPSEN Stock Down 0.9%

The firm has a 50 day moving average price of $31.77 and a 200-day moving average price of $29.90.

About IPSEN

Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.